Medtronic is a global leader in medical technology, focused on developing and providing innovative therapeutic solutions to improve the lives of patients. The company specializes in a wide range of medical devices and therapies, addressing conditions in areas such as diabetes care, cardiovascular health, surgical innovations, and neurological disorders. Medtronic is committed to advancing healthcare through cutting-edge research, collaboration with healthcare providers, and a strong emphasis on patient-centered care, aiming to enhance the quality of life for millions around the world. Read More
(NewsUSA) - Do you ever notice a flutter in your chest? Feel unusually tired even after a good night’s sleep? Get winded from walking up the stairs when that never used to happen? These little signs might not feel like a big deal, but they could point to something more serious: atrial fibrillation, or AFib.
The U.S. Commerce Department, under the Trump administration, has launched a national security review of medical imports—including PPE, consumables, and medical devices—to assess reliance on foreign suppliers for critical health products.
The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on the burgeoning market for weight-loss and diabetes drugs, driven by its groundbreaking GLP-1 agonists. In stark contrast, Johnson & Johnson (NYSE:
Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter for 2025. The company's performance was marked by significant growth across its Innovative Medicine and MedTech segments, showcasing the strategic success of its
Medtronic's Altaviva wins FDA approval as a minimally invasive implant for urge urinary incontinence, offering long-lasting and low-maintenance therapy.
In a financial landscape increasingly dominated by the exhilarating, often volatile, narrative of artificial intelligence, Intuitive Surgical (NASDAQ: ISRG) stands as a testament to steady, fundamental innovation. As the market's gaze fixates on every whisper of AI advancement, the pioneer of robotic-assisted surgery continues its work, quietly refining its formidable
Sunnyvale, CA – September 17, 2025 – Intuitive Surgical (NASDAQ: ISRG), the pioneer and global leader in robotic-assisted surgery, has once again demonstrated its formidable market position with a robust second-quarter 2025 earnings report. The company announced an impressive adjusted Earnings Per Share (EPS) of $2.19, significantly surpassing analyst expectations, coupled
Medtronic (MDT) offers a strong 3.01% dividend yield, a history of reliable payouts, and solid profitability, making it a top candidate for sustainable income investors.
The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is fundamentally altering the landscape of medical treatment and diagnostics, promising a future of more personalized, precise, and preventive medicine. At the forefront of this
Medtronic plc is a global medical device manufacturer with leadership positions in the pacemaker, defibrillator, orthopedic, diabetes management, and other medical markets.
MDT stock shows strong technical momentum and a high-quality consolidation pattern, suggesting a potential breakout setup with a clear risk-reward entry point.
